Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreUtilising the extensive range of data assets exclusively available to IQVIA, combined with our market leading expertise, we are able to support the NHS meet the challenge of delivering high quality, efficient and cost effective healthcare by identifying actionable insight and realising the value in data.
Learn MoreWe believe in the UK’s potential to become a global leader in the life sciences sector, and our investments announced in the 2018 Second Life Sciences Sector Deal further support the UK Government and the industry’s aim to make that potential a reality.
Learn MoreWe are committed to providing solutions that inform and enable all stakeholders across UK healthcare, to innovate with confidence, maximise opportunities, and, ultimately, drive human health outcomes forward.
Learn MoreIQVIA’s Pharmacy Communications offers pharma companies a simple and cost-effective channel to communicate product changes, updates and patient advice directly to patients via pharmacists.
Learn MoreExplore our library of resources spanning the healthcare & life science ecosystem on the latest topics, trends, and market developments that matter to you.
Learn More“Brexit could provide UK Life Sciences with the opportunity to become a global leader in the uptake of innovative medicines”
A new white paper by IQVIA and Public Policy Projects (PPP) analyses the ability of the Life Sciences Industrial Strategy and Sector Deal to meet the challenges raised by Brexit. Where there are gaps, it specifically calls on the Government to place these issues at the centre of the deal it seeks during negotiations with EU partners. The white paper demonstrates the value of medicines through the use of Real-World Evidence and how the UK’s unique health data ecosystem can position it as the global leader in this evolving science, benefitting NHS patients and payers alike.
It makes 9 recommendations: